COMMUNIQUÉS West-GlobeNewswire

4DMT Announces New Employment Inducement Grants
17/01/2026
EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025
17/01/2026
Châtillon, France, 16 janvier 2026 DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW [...]
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
17/01/2026
Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is [...]
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
16/01/2026
MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ ( Bi [...]
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
16/01/2026
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
16/01/2026
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT SOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical- [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, [...]
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
16/01/2026
HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in [...]
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14 [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
16/01/2026
SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
16/01/2026
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials 1 Distinction expedites development and review of treatments for serious conditions that may [...]
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
16/01/2026
American Heart Association consortium advances development of evidence-based health tech solutions AUSTIN, Texas, Jan. 16, 2026 (GLOBE NEWSWIRE) -- MicroTransponder®, Inc. , a commercial-stage medical technology company [...]
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
16/01/2026
Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB [...]
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board
16/01/2026
TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of [...]
Clene to Present at the Emerging Growth Conference
16/01/2026
SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company [...]

Pages